Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

NETWORK 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Breast 1

Conditions

Endometrial Neoplasms 2Endometrial Adenocarcinoma 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 136pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Drug Therapy 29Letrozole 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23Albumin-Bound Paclitaxel 23durvalumab 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20camrelizumab 20Specimen Handling 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Medroxyprogesterone × Gynecologic × Clear all
NCT00064025 2016-04-11

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

GOG Foundation

Phase 2 Completed
75 enrolled 6 charts
Gynecologic

Endometrial Adenocarcinoma

NCT00003179 2013-06-10

Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer

GOG Foundation

Phase 2 Terminated
360 enrolled
Gynecologic

Endometrial Neoplasms

NCT00033358 2013-05-03

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡